IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:) Group Art Unit: 1649	
David Bar-Or	Confirmation No.: 2007	
Serial No.: 10/679,699) Examiner: Gregory S. Emch	
Filed: October 2, 2003)	
Atty. File No.: 4172-85) INFORMATION DISCLOSURE	
Entitled: "Diagnosis and Monitoring of Diseases") <u>STATEMENT</u>	
) Electronically Submitted	
) Modelomourly Submitted	
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450		
Dear Sir:		
The references cited on attached Form PTO-1449 are being called to the attention of the Examiner. Copies of the cited non-patent and/or foreign references are enclosed herewith. Copies of the cited U.S. patents and/or patent applications are enclosed herewith. Copies of the cited U.S. patents/patent application publications are not enclosed in accordance with 37 C.F.R. § 1.98(a). Copies of the cited references are not enclosed, in accordance with 37 C.F.R. § 1.98(d), because the references were cited by or submitted to the U.S. Patent and Trademark Office in prior application Serial No		
Submission of the above information is not i		
is citable under the statutes or rules to support a rejection, that any item disclosed		

pertinence of any reference without the benefit of hindsight, nor should an inference be 1

represents analogous art, or that those skilled in the art would refer to or recognize the

drawn as to the pertinence of the references based on the order in which they are presented. Submission of this statement should not be taken as an indication that a search has been conducted, or that no better art exists.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application and the references made of record therein.

FEES

37 CFR L97(b): No fee is believed due in connection with this submission, because the information disclosure statement submitted therewith is satisfies one of the following conditions ("X" indicates satisfaction): Within three months of the diffing date of a national application other than a continued prosecution application under 37 CFR L35(d), or Within three months of the date of entry into the national stage of an international application as set forth in 37 CFR L491 or Before the mailing date of a first Office Action on the merits, or Before the mailing of a first Office action after the filing of a request for continued examination under 37 CFR L141. Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970.
37 CFR L37(c): The information disclosure statement transmitted berevith is being filed after all the above conditions (37 CFR L37(b)), but before the numiling date of see of the following conditions: (1) a final action under 37 CFR. L3113 or (2) a notice of allowance under 37 CFR. L311, or (3) an action that otherwise closes prosecution in the application. This information Disclosure Statement is accompanied by A Certification (below) as specified by 37 CFR. L37(c). Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970. OR Please charge Deposit Account 19-1970 the amount of \$180.00 for the fee set forth in 37 CFR. L17(p) for submission of an information disclosure statement. Please credit any overpayment or charge any underpayment to Deposit Account 19-1970.
37 CFR 1.97(d): This Information Disclosure Statement is being submitted after the period specified in 37 CFR 1.97(c). This information Disclosure Statement include a Certification (below) as specified by 37 C.F.R. 1.97(e). AND Applicants hereby requests consideration of the reference(s) disclosed herein. Please charge Deposit Account 19-1970 in the amount of \$180.00 under 37 C.F.R. 1.17(p). Please credit any overpayment or charge any underpayment to poposit Account 19-1970 in the amount of \$180.00 under 37 C.F.R. 1.17(p). Please redit any overpayment or charge any underpayment to poposit Account 19-1970. Election to pay the fee should not be taken as an indication that applicant(s) earnor execute a

Certification (37 C.F.R. 1.97(e)) (Applicable only if checked) \boxtimes The undersigned certifies that: Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement, 37 C.F.R. 1.97(e)(1). A copy of the communication from the foreign patent office is enclosed. OR No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(2).

Respectfully submitted,

SHERIDAN ROSS P.C.

y: ____

Date: 4 May 2009

Robert D. Traver Registration No. 47999

1560 Broadway, Suite 1200 Denver, Colorado 80202-5141

(303) 863-9700

3